Q-omics provides the consensus-scored STC1 profile across patient tissues and cancer cell-line models. STC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, STC1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, STC1 RNA expression shows 17,709 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where STC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STC1 survival associations across molecular data types. STC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STC1 RNA expression–survival associations across cancer types. High STC1 expression shows unfavorable associations in KIRP, UVM, STAD, CESC, THCA and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for STC1 RNA expression.
This table summarizes STC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STC1 shows lower tumor expression in KICH and KIRP and higher tumor expression in HNSC, COAD, LIHC and READ. The HNSC box plot shows higher STC1 RNA expression in tumor versus normal tissue (log2 FC = +2.084, t-test p < 0.001).
This table shows molecular features associated with STC1 in patient tissues and cancer cell lines. In patient samples, STC1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
